Can-Fite Biopharma LTD. (CANF) — 20-F Filings
All 20-F filings from Can-Fite Biopharma LTD.. Browse 3 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (3)
-
Can-Fite's Losses Mount to $9.8M in 2025 Amid Reverse Split
— Mar 26, 2026 Risk: high
Can-Fite BioPharma Ltd. (CANF) reported a net loss of approximately $9.8 million in 2025, an increase from $7.9 million in 2024 and $7.6 million in 2023, bringi -
Can-Fite BioPharma Files 2024 Annual Report
— Apr 14, 2025 Risk: medium
Can-Fite BioPharma Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Israel, is involved in th -
Can-Fite BioPharma Ltd. Files 2023 Annual Report on Form 20-F
— Mar 28, 2024 Risk: low
Can-Fite BioPharma Ltd. (CANF) filed a Foreign Annual Report (20-F) with the SEC on March 28, 2024. Can-Fite BioPharma Ltd. filed its annual report on Form 20-F
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX